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ORIGINAL ARTICLE: INFERTILITYSetting: Not applicable.
Patient(s): Serum samples from 1,468 infertile women were utilized.
Intervention(s): None.
Main Outcome Measure(s): Cumulative conception, clinical pregnancy, miscarriage, and live birth rates were calculated.
Result(s): Conception, clinical pregnancy, miscarriage, and live birth rates did not differ between patients with TSHR2.5 mIU/L vs.
TSH< 2.5 mIU/L. Women with anti-TPO antibodies had similar conception rates (33.3% vs. 36.3%) but higher miscarriage rates (43.9%
vs. 25.3%) and lower live birth rates (17.1% vs. 25.4%) than those without anti-TPO antibodies. Adjusted, multivariable logistic
regression models confirmed elevated odds of miscarriage (odds ratio 2.17, 95% confidence interval 1.12–4.22) and lower odds of
live birth (oddr ratio 0.58, 95% confidence interval 0.35–0.96) in patients with anti-TPO antibodies.
Conclusion(s): In infertile women, preconceptional TSHR2.5 mIU/L is not associated with adverse reproductive outcomes; however,
anti-TPO antibodies are associated with increased risk of miscarriage and decreased probability of live birth.
Clinical Trial Registration Number: PPCOS II NCT00719186; AMIGOS NCT01044862. (Fertil Steril 2017;108:843–50. 2017 by
American Society for Reproductive Medicine.)
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16110-fertility-and-sterility/posts/19177-24425E levations in thyroid-stimulating hormone (TSH) andthe presence of anti–thyroid peroxidase (TPO) anti-bodies during pregnancy have been associated with
miscarriage, preterm birth, and adverse perinatal outcomes
(1). Therefore, in infertile women, thyroid supplementation
is commonly prescribed to keep TSH levels to <2.5 mIU/L,
in accordance with recommendations made in 2012 by the
Endocrine Society (2). However, evidence supporting the rela-
tionship between TSH levels or anti-TPO antibodies and
pregnancy-related outcomes of conception, miscarriage,
and live birth in infertile women is lacking.
Thyroid hormones seem to play an important role in
implantation and early pregnancy (3, 4). Thyroid dysfunction
in the form of hypothyroidism affects 4.6% of the US
population (5). Subclinical hypothyroidism, defined as a TSH
level above the 97.5th percentile for gestational age and a free
T4 level within normal limits, has been found in 2.3% of
pregnant women (6, 7) and is associated with an increased risk
of subfertility and adverse perinatal outcomes (1, 2), including
gestational complications, placental abruption, preterm birth
(2, 7), and miscarriage (3, 4). Thyroid autoimmunity, the most
common cause of hypothyroidism, has also been
independently associated with adverse reproductive outcomes.
Moreover, in euthyroid women with TSH levels <2.5 mIU/L,
antithyroid antibodies have been associated with preterm
delivery (5, 8, 9) and miscarriage (6, 7, 10).
In 2012 the Endocrine Society recommended evaluation of
thyroid function in infertile women before pregnancy. Treat-
ment with thyroid supplementation was advised to achieve a
TSH level <2.5 mIU/L (1, 2). Thyroid autoimmunity was not
included as a criterion for thyroid supplementation in these
recommendations. These recommendations were based on the
findings of a large study in early pregnancy, which showed
that anti-TPO antibody–negative women with first-trimester
TSH levels >2.5 mIU/L but <5.0 mIU/L had a higher miscar-
riage rate as compared with women with TSH levels <2.5
mIU/L (3). Women in this study were not infertile and
conceived without treatment. Evaluation of thyroid function
was performed in early pregnancy, rather than before concep-
tion. Despite these nuances, preconceptional screening of infer-844tile women for thyroid dysfunction and treatment of
subclinical hypothyroidism with thyroid supplementation
was recommended (2). However, in infertile women, the role
of preconceptional TSH levels of 2.5–5 mIU/L and anti-TPO
antibodies on fertility and pregnancy outcomes in an infertile
population is unknown. Current American College of Obstetri-
cians and Gynecologists recommendations do not advise
universal screening in pregnancy for either thyroid function
or antithyroid antibodies (11), and recent American Society
for Reproductive Medicine guidelines (12) question the rela-
tionship of TSH levels to infertility and miscarriage. While
acknowledging the low quality of existing evidence, the Amer-
ican Thyroid Association recommends that thyroid supplemen-
tation be considered in women with subclinical
hypothyroidism or TPO antibodies undergoing assisted repro-
ductive technology (13).
To help address this clinical question, we sought to inves-
tigate the impact of preconceptional elevated TSH levels and
presence of anti-TPO antibodies on reproductive success in
infertile women. We hypothesized that in infertile women,
preconceptional TSH levelsR 2.5 mIU/L would be associated
with lower conception and live birth rates and that the pres-
ence of preconceptional anti-TPO antibodies would be associ-
ated with higher rates of miscarriage.MATERIALS AND METHODS
A secondary analysis of data from two multicenter, random-
ized, controlled trials conducted by the Reproductive Medi-
cine Network of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development was
performed. Methods for the design and recruitment of
patients in the Pregnancy in Polycystic Ovary Syndrome II
(PPCOS II; clinicaltrials.gov NCT00719186) (14, 15) and the
Assessment of Multiple Intrauterine Gestations from
Ovarian Stimulation (AMIGOS; clinicaltrials.gov
NCT01044862) (16, 17) have previously been reported. The
PPCOS II trial (N ¼ 750) was a multicenter, prospective,
double-blind, randomized, clinical trial of clomiphene citrate
vs. letrozole for the treatment of infertility in patients withVOL. 108 NO. 5 / NOVEMBER 2017
TABLE 1
Study population demographics and baseline ovarian reserve
parameters.
Variable
All patients
(N[ 1,468)
Age (y) 30.5  4.5
BMI (kg/m2) 30.7  8.9
Race
White 1,163/1,468 (79.2)
Black or African American 171/1,468 (11.7)
Other 134/1,468 (9.1)
Ethnic group
Not Hispanic or Latino 1,266/1,468 (86.2)
Hispanic or Latino 202/1,468 (13.8)
Reason for infertility
No diagnosed reason for infertility 829/1,468 (56.5)
Ovulatory dysfunction (PCOS) 602/1,468 (41.0)
Other reason 37/1,468 (2.5)
Length of attempting conception (mo) 37.8  31.7
Prior live birth 292/1,468 (19.9)
Education
High school graduate or less 226/1,468 (15.4)
College graduate or some college 959/1,468 (65.3)
Graduate degree 283/1,468 (19.3)
History of smoking
Current smoking 172/1,468 (11.7)
Quit smoking 400/1,468 (27.3)
Never smoked 896/1,468 (61.0)
Fasting serum FSH (mIU/mL) 6.7  3.0
Baseline E2 (pg/mL) 43.5  36.3
Baseline AMH (ng/mL) 5.2  5.7
Antral follicle count: both ovaries 33.3  24.6
Note: Values are mean SD or number of subjects/total number (percentage). AMH¼ anti-
m€ullerian hormone; BMI ¼ body mass index; FSH ¼ follicle-stimulating hormone; PCOS ¼
polycystic ovary syndrome.
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Fertility and Sterility®polycystic ovary syndrome. The AMIGOS trial (N¼ 900) was a
multicenter, prospective, randomized, clinical trial of aroma-
tase inhibitors vs. clomiphene citrate vs. gonadotropins com-
bined with IUI for the treatment of unexplained infertility.
Inclusion and exclusion criteria for this analysis were inten-
tionally structured with common criteria to allow for contri-
bution of patients from both trials to maximize power.
Inclusion criteria required normal TSH, as determined locally
by the recruiting center. Patients with uncorrected thyroid
disease (defined as TSH <0.2 mIU/L or >5.5 mIU/L) were
excluded. Institutional review board approval was obtained
at each participating institution, and written informed
consent was obtained. A separate consent was obtained for
storage and use of deidentified samples for future research.
In both trials, serum samples were collected before fertility
treatment, stored at 80C, and subsequently assayed
centrally at the Ligand Assay Core laboratory at the University
of Virginia for both TSH and anti-TPO antibodies. Thyroid-
stimulating hormone was measured using the Immulite 2000
system (range: euthyroid ¼ 0.4–4 uIU/mL, hyperthyroid ¼
<0.01 uIU/mL; intra-assay coefficient of variation [CV]
3.6%; interassay CV 4.7%; Siemens). Assays for anti-TPO
antibodies were not part of the original study protocol and
were only performedon samples authorized for future research.
Anti-TPO antibodies were measured using the antithyroid
peroxidase antibody assay on the Immulite 2000 system
(range: positive>35 IU/mL. Interassay CVs performed at three
levels: 20 IU/mL (10%), 70 IU/mL (5%), and 200 IU/mL (5%).
Pregnancies were detected by serum hCG levels, then followed
by transvaginal ultrasoundbetween6and9weeks’gestation to
document fetal viability. Pregnancy outcomes were confirmed
by review and detailed follow-up of medical records.
We defined elevated TSH as TSHR2.5 mIU/L and euthyr-
oidism as a TSH <2.5 mIU/L. We defined positive anti-TPO
antibodies as >35 IU/mL, per assay specifications. Outcomes
of interest for this study included cumulative rates of concep-
tion, clinical pregnancy, first-trimester miscarriage, and live
birth. Conception was defined as a rising serum level of hCG
on two consecutive tests (AMIGOS) or a serum level of hCG
of >10 mIU/mL (PPCOS II). Clinical pregnancy was confirmed
by the ultrasoundfinding of a gestational sacwith a fetal heart-
beat. Miscarriage included biochemical pregnancies and losses
within the first trimester. Live birth was noted with the birth of
a live-born infant after 20 weeks’ gestation. For this analysis
women who were noted to use thyroid medication during the
study or screening (n ¼ 157) were excluded.
Bivariate analyses, includingWilcoxon rank–sum tests, c2
analyses, and Fisher's exact tests, were performed, where
appropriate, to assess the relationship between other covariates
with TSH R2.5 mIU/L and presence of TPO antibodies. Such
bivariate analyses were used to compare each outcome
(conception, miscarriage, and live birth) by TSH R2.5 mIU/L
and presence of TPO antibodies and covariates. Subsequently,
logistic regression models were created to determine the inde-
pendent association between elevated TSH or thyroid autoim-
munity and each outcome, adjusting for age, treatment arm,
body mass index (BMI), prior live birth, duration of infertility,
history of smoking, educational status, and ovarian reserve.
Sensitivity analyses were also conducted using TSH as aVOL. 108 NO. 5 / NOVEMBER 2017continuous variable. These covariates were selected on the ba-
sis of existing analyses for the same data (18). SAS 9.3 (SAS
Institute) was used for all analyses. A two-tailed P value
< .05 was considered statistically significant.
RESULTS
There were 1,650 women enrolled in the two trials (750
couples in the PPCOS II trial and 900 couples in the AMIGOS
trial). After excluding thyroid medication users (n¼ 157) and
patients with missing TSH values (n¼ 30), 1,468 were eligible
for TSH analysis. After accounting for patients who did not
consent for future studies, 1,429 were available for analysis
of anti-TPO antibodies.
At baseline the participants had a mean (SD) age of 30.5
 4.5 years, with a mean BMI of 30.7 8.9 kg/m2. The sample
was 79.2% white and 13.8% Hispanic. Sixty-five percent of
the women studied reported being a college graduate or
having some college education, and 19.3% had a graduate
degree or beyond. On average, couples had been attempting
to conceive for more than 3 years at the time of enrollment.
Although most women were never-smokers, 11.7% were
current smokers (Table 1).
Thyroid-stimulating hormone averaged 1.9  1.0 mIU/L,
median 1.7 mIU/L and interquartile range 1.2–2.4 mIU/L, with
a full range of 0.0075–7.16 mIU/L. A total of 322 patients
(21.9%) had TSH R2.5 mIU/L. Among those with TSH R2.5845
ORIGINAL ARTICLE: INFERTILITYmIU/L, the average TSHvaluewas 3.3 0.8mIU/L. One hundred
twenty-three women (8.6%) had positive anti-TPO antibodies.
When grouped by presence of elevated TSH and presence
of anti-TPO antibodies, there were no statistically significant
differences in age, FSH, or antim€ullerian hormone (AMH) be-
tween those with and without TSH R2.5 mIU/L or between
those with and without anti-TPO antibodies. Women with
TSH R2.5 mIU/L were more likely to be Caucasian and had
significantly higher BMI and baseline E2 levels compared
with euthyroid women as defined for this study. Women
with anti-TPO antibodies were more likely to be Caucasian.
Women with no diagnosed reason for infertility were less
likely to have a TSHR2.5 mIU/L or have anti-TPO antibodies.
There were no significant differences in demographic charac-
teristics or ovarian reserve parameters of basal FSH, basal E2,
or AMH between the groups with anti-TPO antibodies or
without. Current smokers were more likely to have a TSH
<2.5 mIU/L and to be negative for anti-TPO antibodies
compared with past smokers and never-smokers (Table 2).
Pregnancy rates, miscarriage rates, and live birth rates
were not significantly different between women with TSH
levels R2.5 mIU/L and women with TSH levels <2.5 mIU/L
according to the bivariate analysis (Table 3). Multivariable
logistic regression indicated that there was no difference in
the odds of conception, clinical pregnancy, miscarriage, or
live birth in women with TSH levels R2.5 mIU/L compared
with women with TSH levels <2.5 mIU/L (Fig. 1). To furtherTABLE 2
Demographic characteristics and baseline ovarian reserve measures com
Variable
TSH<2.5 mIU/L
(n[ 1,146)
TSH ‡2.5
(n[ 3
Age (y) 30.5  4.5 30.6 
BMI (kg/m2) 30.2  8.5 32.3 
Race
White 888/1,146 (77.5) 275/322
Black or African American 152/1,146 (13.3) 19/322
Other 106/1,146 (9.3) 28/322
Ethnic group
Not Hispanic or Latino 985/1,146 (86.0) 281/322
Hispanic or Latino 161/1,146 (14.0) 41/322
Reason for infertility
No diagnosed reason for infertility 665/1,146 (58.0) 164/322
Ovulatory dysfunction (PCOS) 458/1,146 (40.0) 144/322
Other reason 23/1,146 (2.0) 14/322
Length of attempting conception (mo) 37.3  31.2 39.3 
Prior live birth 235/1,146 (20.5) 57/322
Education
High school graduate or less 172/1,146 (15.0) 54/322
College graduate or some college 755/1,146 (65.9) 204/322
Graduate degree 219/1,146 (19.1) 64/322
History of smoking
Current smoking 142/1,146 (12.4) 30/322
Quit smoking 308/1,146 (26.9) 92/322
Never smoked 696/1,146 (60.7) 200/322
Fasting serum FSH (mIU/mL) 6.6  3.0 6.8 
Baseline E2 (pg/mL) 42.2  33.3 48.5 
Baseline AMH (ng/mL) 5.2  5.7 5.1 
Antral follicle count: both ovaries 32.8  23.6 35.1 
Note: Values are mean SD or number of subjects/total number (percentage). AMH¼ antim€ullerian
syndrome; TPO ¼ anti-thyroid peroxidase; TSH ¼ thyroid-stimulating hormone.
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846investigate the lack of association between TSH levels and
pregnancy and miscarriage rates, a logistic regression was
conducted with TSH as a continuous variable, and again no
association was observed.
In women with detectable anti-TPO antibodies, the
miscarriage rate was significantly higher and the live birth
rate was significantly lower than that of women without
anti-TPO antibodies (Table 3). Conception and clinical preg-
nancy rates did not differ by presence of TPO antibodies.
Multivariable regression indicated that women with antithy-
roid antibodies had 2.17 times (95% confidence interval [CI]
1.12–4.22) the odds of miscarriage than women without anti-
bodies (Fig. 1). Womenwith antibodies did not have decreased
odds of conception or clinical pregnancy, but they were
significantly less likely to have a live birth, according to
adjusted analyses (odds ratio 0.58, 95% CI 0.35–0.96)
(Fig. 1). When using anti-TPO as a continuous variable, no
significant association between the level of anti-TPO anti-
bodies and miscarriage (adjusted odds ratio 1.001, 95% CI
0.999–1.002, P¼ .42) or live birth (adjusted odds ratio 1.000,
95% CI 0.999–1.001, P¼ .67) was found.DISCUSSION
In this large study of prospectively recruited infertile women,
we found no association of preconceptional TSH levels
between 2.5 and 5 mIU/L with conception, miscarriage, orpared by TSH levels and presence of antithyroid antibodies.
mIU/L
22)
P
value
Negative anti-TPO
antibody
(n[ 1,306)
Positive anti-TPO
antibody
(n[ 123)
P
value
4.5 .77 30.4  4.6 31.0  4.2 .22
10.1 .004 30.8  9.0 30.1  8.5 .49
.001 .04
(85.4) 1,028/1,306 (78.7) 107/123 (87.0)
(5.9) 159/1,306 (12.2) 6/123 (4.9)
(8.7) 119/1,306 (9.1) 10/123 (8.1)
.54 .43
(87.3) 1,127/1,306 (86.3) 103/123 (83.7)
(12.7) 179/1,306 (13.7) 20/123 (16.3)
.01 .047
(50.9) 722/1,306 (55.3) 70/123 (56.9)
(44.7) 555/1,306 (42.5) 46/123 (37.4)
(4.4) 29/1,306 (2.2) 7/123 (5.7)
33.4 .48 37.8  32.0 39.4  31.8 .25
(17.7) .27 263/1,306 (20.1) 17/123 (13.8) .09
.66 .83
(16.8) 205/1,306 (15.7) 17/123 (13.8)
(63.4) 850/1,306 (65.1) 83/123 (67.5)
(19.9) 251/1,306 (19.2) 23/123 (18.7)
.31 .02
(9.3) 163/1,306 (12.5) 5/123 (4.1)
(28.6) 353/1,306 (27.0) 38/123 (30.9)
(62.1) 790/1,306 (60.5) 80/123 (65.0)
3.0 .10 6.7  3.1 6.3  1.7 .14
45.0 .02 43.4  33.1 47.9  63.2 .87
5.9 .19 5.3  5.7 5.3  6.7 .39
28.0 .65 33.6  25.1 33.1  22.1 .91
hormone; BMI¼ bodymass index; FSH¼ follicle-stimulating hormone; PCOS¼ polycystic ovary
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TABLE 3
Unadjusted reproductive outcome measures.
Variable Conceptions P value
Clinical
pregnancies P value
First-trimester
pregnancy
lossesa P value Live birth P value
Study (n ¼ 1,498) .40 .30 .99 .59
AMIGOS 286/775 (36.9) 228/775 (29.4) 77/286 (26.9) 195/775 (25.2)
PPCOSII 241/693 (34.8) 187/693 (27.0) 65/241 (27.0) 166/693 (24.0)
TSH groups (n ¼ 1,498) .83 .32 .21 .37
TSH <2.5 mIU/L 413/1,146 (36.0) 331/1,146 (28.9) 106/413 (25.7) 288/1,146 (25.1)
TSHR2.5 mIU/L 114/322 (35.4) 84/322 (26.1) 36/114 (31.6) 73/322 (22.7)
Thyroid antibody groups (n
¼ 1,459)
.51 .22 < .01 .04
Negative anti-TPO Ab 474/1,306 (36.3) 376/1,306 (28.8) 120/474 (25.3) 332/1,306 (25.4)
Positive anti-TPO Ab 41/123 (33.3) 29/123 (23.6) 18/41 (43.9) 21/123 (17.1)
TSH and thyroid antibody
combined groups
(n ¼ 14,59)
.29 .35 .02 .14
TSH<2.5 and anti-TPOAb
negative
375/1,040 (36.1) 304/1,040 (29.2) 89/375 (23.7) 267/1,040 (25.7)
TSH<2.5 and anti-TPOAb
positive
29/73 (39.7) 20/73 (27.4) 14/29 (48.3) 15/73 (20.6)
TSHR2.5 and anti-TPO
Ab negative
99/266 (37.2) 72/266 (27.1) 31/99 (31.3) 65/266 (24.4)
TSHR2.5 and anti-TPO
Ab positive
12/50 (24.0) 9/50 (18.0) 4/12 (33.3) 6/50 (12.0)
Note: Values in parentheses are percentages. Ab ¼ antibody; AMIGOS ¼ Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation; PPCOS II ¼ Pregnancy in Polycystic Ovary Syn-
drome II; TPO ¼ anti-thyroid peroxidase; TSH ¼ thyroid-stimulating hormone.
a Pregnancy losses before 13 weeks/conception.
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Fertility and Sterility®live birth rates. In contrast, we found that preconceptional
anti-TPO antibodies were associated with increased miscar-
riage rates as well as decreased live birth rates. Our data
suggest that preconceptional TSH levels R2.5 mIU/L are
not a risk factor for poorer reproductive outcomes, but instead
that preconceptional presence of anti-TPO antibodies may be
of concern. These findings call into question the practice of
preconceptional identification and treatment of women
with TSH levelsR2.5 mIU/L but less than the upper limit of
normal to improve obstetric outcomes (10, 12). The
conundrum remains whether preconceptional identification
of euthyroid infertile women who have antithyroid
antibodies is beneficial, and whether treatment, if any,
improves pregnancy chances and outcomes.
Our study did not demonstrate an association between
elevated preconception TSH levels in infertile women and
pregnancy, miscarriage, or live birth rates. Our findings differ
from a number of prior studies that found associations
between lower pregnancy rates and elevated TSH levels but
that included patients who were recruited in early pregnancy
rather than preconceptionally (3, 7, 19). The lack of
association between preconceptional TSH levels and
pregnancy rates is in agreement with recent studies
conducted in populations of infertile women (20, 21). In
regard to miscarriage risks, our data did not demonstrate a
correlation of TSH levels with miscarriage rates, which is in
contrast to observations in prior reports (20, 22). Our
findings are similar to those of other, smaller studies, where
TSH was assessed before treatment of infertile women (21,
23, 24) and those with a history of pregnancy loss (25). In
contrast, a recent study of infertile women who underwent
IUI found significantly lower odds of miscarriage andVOL. 108 NO. 5 / NOVEMBER 2017higher odds of live birth in women with elevated
preconception TSH values (2.5–4.9 mIU/L) (20). Our results
also differ from those of a number of studies that have
found that higher TSH values, when assessed during
pregnancy, are associated with miscarriage (3, 22). Thus, the
timing of screening for TSH level is likely important, with
questionable value of screening for TSH preconceptionally.
Nonetheless, the value of screening using TSH levels even
in pregnancy is still controversial and not established. In
addition, it may be possible that the discrepant results
between studies may be related to the etiology of
miscarriage. Studies to date have not established an
association between hypothyroidism and euploid pregnancy
losses. It should be noted that a majority of miscarriages are
caused by aneuploidy, and it could be possible that high
TSH levels are a marker of a pregnancy destined to fail
because of aneuploidy rather than a causative factor.
The literature has been inconsistent regarding the associa-
tion between thyroid antibodies and miscarriage risks. One
study postulated that miscarriages within a population of
euthyroid women with positive antithyroid antibodies are
due to deficiencies in thyroid function that manifest not
preconceptionally but during early pregnancy (26). A smaller
study observed higher TSH levels in patients with thyroid auto-
immunity but no difference in the miscarriage rate (27). As in
prior studies, we found a significant association of antithyroid
antibodies with both higher miscarriage rates and lower live
birth rates (10). We found that presence of antithyroid anti-
bodies preconceptionally increases the probability of miscar-
riage and lowers the probability of live birth after treatment
of infertile women. A number of smaller studies have described
similar findings (10, 28), and yet others report no association847
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ORIGINAL ARTICLE: INFERTILITY(19,25,29–31). Many studies are limited by small numbers of
outcomes, inconsistent timing of thyroid testing, and
incomplete follow-up. Comparison of results from various
studies is further complicated by inclusion of different popula-
tions. Nonetheless, a systematic review of nine studies
concluded that pregnant women with anti-TPO antibodies
have higher miscarriage rates (32). One study postulated that
miscarriages within a population of euthyroid women with
positive antithyroid antibodies are due to deficiencies in thy-
roid function that manifest not preconceptionally but during
early pregnancy (26). A study by Korevaar et al. (33) also
concluded that antithyroid antibodies are associated with
diminished adaptation of the thyroid gland to pregnancy.
They studied the relationship between TSH levels and hCG
rise in early pregnancy and found that in women with thyroid
antibodies, the thyroidal response to hCG was attenuated (33).
At least one study suggests that treatment of women with
TPO antibodies and no other evidence of thyroid dysfunction
with levothyroxine supplementation decreases the risk of848miscarriage (19). Yet others postulate that thyroid dysfunction
is associated with alterations in cytokines and T-helper cells
(34). Our findings support an association between the precon-
ceptional presence of antithyroid antibodies and an increased
risk of miscarriage. Currently there is no established therapy
for thyroid autoimmunity to improve reproductive outcomes.
This study has a number of strengths. Our investigation
was conducted in multiple academic centers throughout the
United States and therefore represents a sample population
of multiple ethnicities from multiple geographic areas. This
is in contrast to prior well-performed, large trials that were
limited in generalizability owing to the single-site nature of
their patient population (3). Patients in our study were fol-
lowed through multiple cycles of infertility treatment within
a highly standardized comprehensive study design and
observed throughout pregnancy and delivery. This compre-
hensive evaluation of study participants from initiation of
treatment through live birth is unique and provides an impor-
tant perspective (35).VOL. 108 NO. 5 / NOVEMBER 2017
Fertility and Sterility®All assays for TSH and antithyroid antibodies were per-
formed in a centralized laboratory. This reduced potential
variability between assays and also reduced variations in
categorization of elevated TSH levels or antithyroid antibody
levels. One important aspect of our study is that patients were
recruited before widespread adoption of the 2012 Endocrine
Society guidelines. Therefore, many patients were untreated
but fell into the subclinical hypothyroid range according to
Endocrine Society definitions, providing a robust comparison
group without the confounding factor of thyroid supplemen-
tation. Last, this study encompassed infertile patients with
both polycystic ovary syndrome and unexplained infertility.
Because these two diagnoses are common, this is a substantial
patient subset within the population of infertile women.
However, this selection may have induced bias because
male factor and tubal disease patients are not included.
Our findings are limited by our use of a single, cross-
sectional evaluation of TSH and antithyroid antibodies.
Prior studies have demonstrated acute changes in thyroid
function within an episode of ovarian stimulation (36);
however, because repeated measures of thyroid parameters
were not included in this analysis, we could not assess any
possible effects of elevated serum estrogen levels from
ovarian stimulation. Additionally, free T4 levels were not
included in this analysis. This may have resulted in inclu-
sion of women with undiagnosed thyroid dysfunction.
However, TSH levels alone are typically used for screening
for thyroid function in most clinical settings, and if normal,
no further testing is done. Last, this study did not address
the effect of thyroid supplementation for women with thy-
roid autoimmunity. Although patients taking thyroid sup-
plementation were excluded from the analysis, the
number of subjects taking thyroid supplementation was
less than 10% of the total population, and their exclusion
did not change the results.
In conclusion, this study highlights an association
between anti-TPO antibodies and increased miscarriage rates
and lower live birth rates, and a lack of association between
preconception TSH levels R2.5 mIU/L and conception,
miscarriage, and live birth rates among infertile women
undergoing fertility treatment. These results suggest that
thyroid supplementation in infertile women with TSH levels
R2.5 mIU/L but <5.0 mIU/L may not be beneficial, whereas
women with preconceptional anti-TPO antibodies may be at
risk for decreased reproductive success. These findings differ
from those that formed the basis for the current Endocrine
Society recommendations for screening and subsequent treat-
ment of infertile women with preconceptional TSH levels
>2.5 mIU/L. This analysis characterizes a key group of infer-
tile patients, euthyroid women with anti-TPO antibodies, who
may be at risk for adverse pregnancy outcomes and eventu-
ally overt thyroid disease and for whom increased thyroid
surveillance is potentially beneficial. Future interventional
studies should seek to determine whether these women will
benefit from increased thyroid surveillance and/or treatment
with T4 supplementation andwhether anti-TPO antibodies are
simply a marker of other processes impeding the course of
pregnancy or are the cause of poorer reproductive success.VOL. 108 NO. 5 / NOVEMBER 2017REFERENCES
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